www.emma-madrid.com

Organized by:

Chairs:Jesús F. San-Miguel, Clínica Universidad de Navarra, Pamplona (Spain) Heinz Ludwig, Wilhelminen Cancer Research Institute, Vienna (Austria)

Friday 4th - Saturday 5th

September 2020

22nd EMMA 2020 Virtual Meeting

Central Europe Summer Time (CEST)

Organized by:

Friday, 4th September 2020

09:00 - 09:05 Opening Jesús F. San-Miguel, Heinz Ludwig

09:05 - 10:25 PLENARY SESSION 1: MYELOMA BIOLOGY Moderator: Heinz Ludwig

09:05 - 09:25 Genomics in myeloma: pathogenic and clinical implications Martin Kaiser

09:25 - 09:50 How important are epigenetics in MM Felipe Prósper

09:50 - 10:10 Druggable myeloma therapeutics. Pathogenetic pathways Enrique Ocio

10:10 - 10:25 Experts' discussion around 5 burning questions: 1. What techniques?: clinical meaning of mutations 2. The number of genetics lesions and percentage of abnormal cells matter for clinical decisions? 3. What is the meaning of genetic changes in MGUS and SMM? 4. Clinical future for epigenetics 5. What are the most relevant pathways and drugs in myeloma? Discussants: Martin Kaiser, Felipe Prósper, Enrique Ocio, Pieter Sonneveld10:25 - 10:40 Break

10:40 - 11:35 WORKSHOPS Moderator: Jesús F. San-Miguel10:40 - 11:00 1. Di�cult to treat MM (extramedullary, CNS, oligosecretory, solitary, PCL, biochemical relapse). Kwee Yong 11:00 - 11:20 2. MGUS with systemic manifestations Joan Bladé

11:20 - 11:35 Discussion11:35 - 11:50 Break

11:50 - 12:55 PLENARY SESSION 2: NEW TOOLS FOR TREATMENT MONITORING IN MM PATIENTS Moderator: Heinz Ludwig11:50 - 12:05 NGS Nikhil C. Munshi12:05 - 12:20 Immunophenotyping Bruno Paiva

12:20 - 12:35 MRI and CT-PET Philippe Moreau12:35 - 12:55 Experts' discussion around 5 burning topics: 1. New response criteria 2. Optimal MRD technique 3. Prognostic factors or biomarker for treatment 4. Should we stratify patients? 5. Should we implement PET in routine clinical practice? Discussants: Nikhil C. Munshi, Bruno Paiva, Philippe Moreau, Jesús F. San-Miguel 12:55 - 13:45 Break

13:45 - 14:20 PLENARY SESSION 3: EARLY INTERVENTION IN MYELOMA Moderator: Philippe Moreau

13:45 - 14:05 Smoldering myeloma M. Victoria Mateos

14:05 - 14:20 Experts' discussion on 4 burning topics: 1. How to de�ne high risk 2. Delay progression or cure? 3. Risk adapted management 4. Will the concept of smoldering disappear? Discussants: M. Victoria Mateos, Michele Cavo, Kwee Yong, Nikhil C. Munshi14:20 - 14:35 Break

14:35 - 15:30 PLENARY SESSION 4: FRONT LINE TREATMENT FOR YOUNG PATIENTS WITH MM Moderator: Jesús F. San-Miguel

14:35 - 14:55 Induction and transplant Philippe Moreau

14:55 - 15:15 Consolidation and maintenance Michele Cavo

15:15 - 15:30 Experts' discussion on 5 burning topics: 1. Best induction 2. Early vs. late transplant 3. One vs. two 4. Consolidation & maintenance 5. High risk Discussants: Philippe Moreau, Michele Cavo, Joan Bladé, Meletios A. Dimopoulos15:30 - 15:45 Break

15:45 - 16:40 PLENARY SESSION 5: IMMUNOTHERAPY Moderator: Heinz Ludwig

15:45 - 16:05 Bases for immunotherapy in MM and novel antibodies Niels van de Donk

16:05 - 16:25 Clinical results with CAR-T cells and other adoptive therapies Paula Rodríguez-Otero

16:25 - 16:40 Experts' discussion on 4 burning topics: 1. Is CAR-T the future? 2. CAR-T plus anti-myeloma drugs 3. Bispeci�c antibodies or CAR-T 4. Industry or academia Discussants: Niels van de Donk, Paula Rodríguez-Otero, Philippe Moreau, Pieter Sonneveld16:40 - 16:55 Break

16:55 - 18:00 WORKSHOPS Moderator: Jesús F. San-Miguel16:55 - 17:15 3. Genomics and microenvironment: what a myeloma doctor should know. Nikhil C. Munshi17:15 - 17:45 4. Emergencies and supportive care (cord compression, RI, hyperCa, bone disease, infections…).

Heinz Ludwig

17:45 - 18:00 Discussion

09:00 - 09:40 PLENARY SESSION 6: FRONT LINE TREATMENT FOR ELDERLY PATIENTS WITH MM Moderator: Heinz Ludwig

09:00 - 09:20 How I treat elderly patients Francesca Gay

09:20 - 09:40 Experts' discussion on 5 burning topics: 1. Optimal combination and duration 2. Maintenance/ continuous 3. Do we need alkylators? 4. High risk 5. Frailty Discussants: Francesca Gay, Enrique Ocio, M. Victoria Mateos, Kwee Yong09:40 - 09:55 Break

09:55 - 10:40 PLENARY SESSION 7: THE RELAPSED/ REFRACTORY PATIENTS: RECOMMENDATIONS AND CHALLENGES Moderator: Jesús F. San-Miguel

09:55 - 10:20 How I treat relapsed patients Xavier Leleu

10:20 - 10:40 Experts' discussion on 5 burning topics: 1. Biological relapse versus agresive relapse 2. Early and late relapse and ASCT 3. Triplet versus doublets: is it cost-e�ective? 4. Optimal sequence for new agents 5. Extramedullary relapse Discussants: Xavier Leleu, Heinz Ludwig, Enrique Ocio, Paula Rodríguez-Otero10:40 - 10:55 Break

10:55 - 12:10 PLENARY SESSION 8: HOW I TREAT OTHER MALIGNANT GAMMOPATHIES Moderator: Jesús F. San-Miguel, Heinz Ludwig

10:55 - 11:15 Amyloidosis Giampaolo Merlini

11:15 - 11:35 Waldenstrom macroglobulinemia Meletios A. Dimopoulos

11:35 - 11:55 The relations between academia and industry Pieter Sonneveld

11:55 - 12:10 Questions & discussion

12:10 - 12:15 Closing remarks Jesús F. San-Miguel, Heinz Ludwig

Saturday, 5th September 2020

Organized by:

List of Faculty This meeting is targeted towards myeloma treating physicians who are interested in understanding and discussing the latest developments in myeloma diagnosis and treatment.

Campus Universidad de Navarra

Joan BladéHospital Clínic Universitari, Barcelona (Spain)

Michele CavoSeragnoli Institute of Hematology, Bologna (Italy)

Meletios A. DimopoulosUniversity Athens School of Medicine, Athens (Greece)

Francesca GayUniversità degli Studi di Torino, Turin (Italy)

Martin KaiserThe Royal Marsden NHS Foundation Trust, London (UK)

Xavier LeleuHôpital de la Milétrie - CHU, Poitiers (France)

Heinz LudwigWilhelminen Cancer Research Institute, Vienna (Austria)

M. Victoria MateosHospital Universitario de Salamanca, Salamanca (Spain)

Giampaolo MerliniFondazione IRCCS Policlinico San Matteo, Pavia (Italy)

Philippe MoreauUniversity Hospital Hôtel-Dieu, Nantes (France)

Nikhil C. MunshiDana-Farber Cancer Institute. Harvard Medical School, Boston (USA)

Enrique Ocio Hospital Universitario Marqués de Valdecilla, Santander (Spain)

Bruno PaivaCIMA, Universidad de Navarra, Pamplona (Spain)

Felipe PrósperClínica Universidad de Navarra, Pamplona (Spain)

Paula Rodríguez-OteroClínica Universidad de Navarra, Pamplona (Spain)

Jesús F. San-MiguelClínica Universidad de Navarra, Pamplona (Spain)

Pieter SonneveldErasmus University Medical Center, Rotterdam (The Netherlands)

Niels van de DonkVU University Medical Center, Amsterdam (The Netherlands)

Kwee YongUniversity College London Hospitals NHS Trust, London (UK)

Accreditation

The 22nd EMMA (European Multiple Myeloma Academy) 2020 virtual meeting, 04/09/2020-05/09/2020 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximun of 8 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

(+34) 91 372 02 03 e-mail: emma@doctaforum.comwww.emma-madrid.com

Conference Secretariat:

Platinum

Gold

Silver

Bronze

Collaborator

www.emma-madrid.com

This meeting is organized and hosted byProfessor Jesús F. San-Miguel, Clínica Universidad de Navarra, Pamplona (Spain).

This event is supported by educational grants from: